Shanghai Laishi: 2021 Annual Equity Distribution Implementation Notice
Shanghai Laishi: Explanation on the purchase and sale of assets by listed companies within the first 12 months of this restructuring
Shanghai Laishi: Announcement on developments after disclosing major asset restructuring plans
Shanghai Laishi: Announcement on the progress of planning the suspension of major asset restructuring
Shanghai Laishi: Announcement on the progress of planning the suspension of major asset restructuring
Shanghai Laishi: Announcement on the company signing a share transfer agreement to acquire a subsidiary single plasma collection station
Shanghai Laishi: 2018 Payment, Interest Payment and Delisting Notice of “12 Rexroth Bonds”
Shanghai Laishi: Announcement on matters relating to the acquisition of Biotest by the controlling shareholder
Shanghai Laishi: Annual Report on Fiduciary Management of Corporate Bonds (2016)
Shanghai Laishi: 2012 Corporate Bonds 2017 Tracking Credit Rating Report
Shanghai Laishi: “12 Ryse Bonds” 2017 Interest Payment Announcement
Shanghai Laishi: Announcement on the acquisition of minority shareholder shares of Tonglu Biopharmaceutical Co., Ltd., a holding subsidiary
Shanghai Laishi: Corporate Bond Fiduciary Management Report (2015)
Shanghai Laishi: 2013 Corporate Bonds 2016 Tracking Credit Rating Report
Shanghai Laishi: Announcement on the results of the investor resale implementation of “12 Ryse Bonds”
Shanghai Laishi: “12 Ryse Bonds” 2016 Interest Payment Announcement
Shanghai Laishi: Third indicative announcement on the implementation measures for non-adjustment of the coupon interest rate and investor resale of “12 Ryse Bonds”
Shanghai Laishi: Second indicative announcement on the implementation measures for non-adjustment of the coupon interest rate and investor resale of “12 Ryse Bonds”
Shanghai Laishi: Notice on the Revision of Major Asset Restructurings and Related Transactions Report on Issuing Shares to Purchase Assets and Raise Supporting Funds
Shanghai Laishi: Financial Adviser's Professional Opinion Schedule No. 3 for Mergers, Acquisitions and Restructurings of Listed Companies - Issuing Shares to Purchase Assets
No Data
No Data